Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 10, n. 2, p. s730, 2026. DOI: 10.25251/7mx6d484. Disponível em: https://skin.dermsquared.com/skin/article/view/4039. Acesso em: 1 may. 2026.